Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

ONCT has been the topic of several other reports. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Securities reiterated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $0.53 on Friday. The firm has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. The company’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $3.44. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.